DGIdb - CYP2A6 Gene Record

CYP2A6 1548 Druggable Genome

Alternate Names:

1548
CYTOCHROME P450 FAMILY 2 SUBFAMILY A MEMBER 6
CYP2A6
CPA6
CYP2A
CYP2A3
CYPIIA6
P450C2A
P450PB
122720
2610
ENSG00000255974
OTTHUMG00000182713
ENSG00000198470
CYTOCHROME P450 2A6 (EC 1.14.14.1) (CYPIIA6) (COUMARIN 7-HYDROXYLASE) (IIA3) (CYP2A3) (P450(I)). [SOURCE:UNIPROT/SWISSPROT;ACC:P11509]
1321
P11509
CP2A6_HUMAN
CYTOCHROME P450 2A6
BE0003336
PA121
T06455

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Interpro Name	Cytochrome P450
Uniprot Status	Swiss-Prot
Interpro Type	Family
Interpro Acc	IPR001128
Interpro Short Name	Cyt_P450
Uniprot Evidence	1: Evidence at protein level
Human Readable Name	CYTOCHROME P450
GuideToPharmacology Gene Category Name	CYP2 family
GuideToPharmacology Gene Category ID	262
Gene Biotype	PROTEIN_CODING

(7 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
DRUG METABOLISM
CYTOCHROME P450
ENZYME

Publications:

Asimus S et al., 2008, Artemisinin and CYP2A6 activity in healthy subjects., Eur J Clin Pharmacol
Veiga MI et al., 2009, Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam., Eur J Clin Pharmacol
Kerb R et al., 2009, Pharmacogenetics of antimalarial drugs: effect on metabolism and transport., Lancet Infect Dis
Medhi B et al., 2009, Pharmacokinetic and toxicological profile of artemisinin compounds: an update., Pharmacology
Elsherbiny DA et al., 2008, A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens., J Pharmacokinet Pharmacodyn
Li XQ et al., 2003, Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data., Eur J Clin Pharmacol
Simonsson US et al., 2003, Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9., Clin Pharmacol Ther
Tani N et al., 2014, Rational design of novel CYP2A6 inhibitors., Bioorg Med Chem
Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab
Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab
Komatsu T et al., 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4., Drug Metab Dispos
Kimber-Trojnar Z et al., 2003, Perspectives of losigamone in epilepsy treatment., Pol J Pharmacol
Torchin CD et al., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes., Drug Metab Dispos
Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics
Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics
Hazai E et al., 2002, Reduction of toxic metabolite formation of acetaminophen., Biochem Biophys Res Commun
Chen W et al., 1998, Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6., Chem Res Toxicol
Bergen AW et al., 2015, Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption., PLoS One
Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
Li L et al., 2006, New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes., Drug Metab Dispos
Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett
Kiyotani K et al., 2003, Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)., Pharmacogenetics
Meunier V et al., 2000, Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up., Xenobiotica
Oscarson M et al., 1998, Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase., FEBS Lett
Gao N et al., 2016, Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes., Eur J Pharm Sci
Haberl M et al., 2005, Three haplotypes associated with CYP2A6 phenotypes in Caucasians., Pharmacogenet Genomics
Fukami T et al., 2005, Characterization of novel CYP2A6 polymorphic alleles (CYP2A618 and CYP2A619) that affect enzymatic activity., Drug Metab Dispos
Oscarson M et al., 2002, Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity., Hum Mutat
Yoshida R et al., 2003, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro., Clin Pharmacol Ther
Hadidi H et al., 1997, A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin., Food Chem Toxicol
Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
Fukami T et al., 2005, A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity., Biochem Pharmacol
Xu C et al., 2002, An in vivo pilot study characterizing the new CYP2A67, 8, and *10 alleles., Biochem Biophys Res Commun
Yamano S et al., 1990, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes., Biochemistry
Kitagawa K et al., 2001, CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity., J Biol Chem
Donato MT et al., 2000, CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers., Drug Metab Dispos
Malaiyandi V et al., 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy., Mol Psychiatry
Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J
Nakajima M et al., 2006, Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations., Clin Pharmacol Ther
di Iulio J et al., 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function., Pharmacogenet Genomics
Endo T et al., 2008, Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine., Pharmacogenet Genomics
Nurfadhlina M et al., 2006, CYP2A6 polymorphisms in Malays, Chinese and Indians., Xenobiotica
Gyamfi MA et al., 2005, High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana., Eur J Clin Pharmacol
Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
Tan W et al., 2001, Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population., Int J Cancer
Schoedel KA et al., 2004, Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians., Pharmacogenetics
Kaida Y et al., 2008, The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer., Clin Pharmacol Ther
Fukami T et al., 2004, A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo., Clin Pharmacol Ther
Tan L et al., 2010, The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients., Clin Neurol Neurosurg
Zhang X et al., 2001, Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population., Nihon Arukoru Yakubutsu Igakkai Zasshi
Ishii Y et al., 2010, Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?, Cancer Chemother Pharmacol
Kimura M et al., 2005, Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans., Drug Metab Dispos
Ariyoshi N et al., 2001, A novel single nucleotide polymorphism altering stability and activity of CYP2a6., Biochem Biophys Res Commun
Murai K et al., 2009, Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes., Xenobiotica
Rao Y et al., 2000, Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking., Mol Pharmacol
Djordjevic N et al., 2010, In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population., Eur J Clin Pharmacol
Huang S et al., 2005, CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents., Pharmacogenet Genomics
Audrain-McGovern J et al., 2007, The role of CYP2A6 in the emergence of nicotine dependence in adolescents., Pediatrics
Daigo S et al., 2002, A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur., Pharmacogenetics
Tanii H et al., 2011, Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women., Eur J Clin Pharmacol
Kitagawa K et al., 1999, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP., Biochem Biophys Res Commun
Hirose T et al., 2010, Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer., Oncol Rep
Ariyoshi N et al., 2002, Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers., Cancer Epidemiol Biomarkers Prev
Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
Yamanaka H et al., 2004, Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted., Eur J Pharm Sci
Poland RE et al., 2000, Effect of cigarette smoking on coumarin metabolism in humans., Nicotine Tob Res
Fujieda M et al., 2004, Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers., Carcinogenesis
Minematsu N et al., 2006, Limitation of cigarette consumption by CYP2A64, 7 and *9 polymorphisms., Eur Respir J
Arab-Alameddine M et al., 2009, Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals., Clin Pharmacol Ther
Fukami T et al., 2007, A novel duplication type of CYP2A6 gene in African-American population., Drug Metab Dispos
Ando M et al., 2003, Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults., J Epidemiol
Fujita K et al., 2008, CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1., Cancer Sci
Iwahashi K et al., 2004, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior., Neuropsychobiology
Peamkrasatam S et al., 2006, In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais., Drug Metab Pharmacokinet
Benowitz NL et al., 2006, CYP2A6 genotype and the metabolism and disposition kinetics of nicotine., Clin Pharmacol Ther
Wang J et al., 2006, 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression., Biochem Biophys Res Commun
Smith IE et al., 2003, Aromatase inhibitors in breast cancer., N Engl J Med
Kwon JT et al., 2001, Nicotine metabolism and CYP2A6 allele frequencies in Koreans., Pharmacogenetics
Nakajima M et al., 2004, Novel human CYP2A6 alleles confound gene deletion analysis., FEBS Lett
Borrie AE et al., 2018, Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer., Breast Cancer Res Treat
Nakajima M et al., 2001, Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans., Clin Pharmacol Ther
Paschke T et al., 2001, Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method., Toxicology
Desta Z et al., 2011, Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age., Clin Pharmacol Ther
Lerman C et al., 2015, Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial., Lancet Respir Med
Endo T et al., 2007, Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes., Drug Metab Dispos
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

LOSIGAMONE CYP2A6

Interaction Score: 14.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB
LETROZOLE CYP2A6

Interaction Score: 7.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11394901 16402128 15940289 16952495 19238117 18698229 12802030 16891249 10544257 15660270 20860463 11241319 15475735 16378601 18212800 15592323 9827545 20089352 11725533 19921195 15980104 11237731 19845430 10999944 20155256 16272956 17130279 11434509 12042667 15225612 15900015 21494765 10448083 30094551 20596643 11180041 12325023 12223434 12844137 19604090 11684323 15265511 15308589 21521021 16452582 19225447 11779172 12749606 18380793 14981342 17220563 17112802 21975350

Sources:
PharmGKB
PILOCARPINE CYP2A6

Interaction Score: 6.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11394901 16402128 15940289 16952495 19238117 18698229 16891249 10544257 15660270 20860463 11241319 15475735 18212800 20089352 11725533 19921195 15980104 11237731 19845430 10999944 20155256 16272956 17130279 12042667 15900015 21494765 10448083 20596643 12223434 12844137 19604090 15265511 15308589 21521021 16452582 19225447 11779172 12749606 17178767 18380793 14981342 17220563 17112802

Sources:
PharmGKB
CHEMBL178090 CYP2A6

Interaction Score: 4.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235

Sources:
DrugBank
CHEMBL360998 CYP2A6

Interaction Score: 4.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235

Sources:
DrugBank
CHEMBL178938 CYP2A6

Interaction Score: 4.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235

Sources:
DrugBank
3-FORMYLINDOLE CYP2A6

Interaction Score: 4.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25458499

Sources:
DTC
CHEMBL1770735 CYP2A6

Interaction Score: 4.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25458499

Sources:
DTC
COUMARIN CYP2A6

Interaction Score: 3.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11394901 16679388 10544257 14583682 10923861 9827545 27339126 16041240 15900015 12325023 12844137 9409631 21521021 15993850 11779172 2322567 11278503 11038160

Sources:
PharmGKB DrugBank
ARTEMETHER CYP2A6

Interaction Score: 3.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources:
PharmGKB
CAFFEINE CYP2A6

Interaction Score: 2.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11394901 16402128 15940289 16952495 19238117 18698229 16891249 10544257 15660270 20860463 11241319 15475735 18212800 15592323 20089352 11725533 19921195 15980104 11237731 19845430 10999944 20155256 16272956 17130279 12042667 15900015 21494765 10448083 20596643 12223434 12844137 19604090 15265511 11197315 15308589 21521021 16452582 19225447 11779172 17267622 12749606 18380793 14981342 17220563 17112802

Sources:
PharmGKB
ARTEMISININ CYP2A6

Interaction Score: 2.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources:
PharmGKB
ARTESUNATE CYP2A6

Interaction Score: 2.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources:
PharmGKB
IFOSFAMIDE CYP2A6

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB
CHEMBL1232076 CYP2A6

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235

Sources:
DrugBank
VARENICLINE CYP2A6

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25588294

Sources:
PharmGKB
PHENYTOIN CYP2A6

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB
HALOTHANE CYP2A6

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB
CARBAMAZEPINE CYP2A6

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB
METHOXSALEN CYP2A6

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
BUPROPION CYP2A6

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26132489

Sources:
PharmGKB
FLUOROURACIL CYP2A6

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15940289 19238117 18698229 16378601 19921195 20155256 21494765 19604090 21521021 14981342

Sources:
PharmGKB
COTININE CYP2A6

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ESOMEPRAZOLE CYP2A6

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ACETAMINOPHEN CYP2A6

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26049587 11866476 9548799

Sources:
PharmGKB
CYCLOPHOSPHAMIDE CYP2A6

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB
ZIDOVUDINE CYP2A6

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22960662

Sources:
PharmGKB
DOCETAXEL CYP2A6

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19604090

Sources:
PharmGKB

Ensembl: ENSG00000255974
- Version: 101_38
Alternate Names:

CYP2A6 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

RussLampel: ENSG00000198470

Version: 26-July-2011

Alternate Names:

ENSG00000198470 Ensembl Gene Id

CYTOCHROME P450 2A6 (EC 1.14.14.1) (CYPIIA6) (COUMARIN 7-HYDROXYLASE) (IIA3) (CYP2A3) (P450(I)). [SOURCE:UNIPROT/SWISSPROT;ACC:P11509] Description

CYP2A6 Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

HopkinsGroom: P11509
- Version: 11-September-2012
Alternate Names:

P11509 Uniprot Accession

CYP2A6 Uniprot Gene Name

ENSG00000255974 Ensembl Gene Id

Gene Info:

Interpro Name Cytochrome P450

Uniprot Status Swiss-Prot

Interpro Type Family

Gene Categories:

DRUGGABLE GENOME, CYTOCHROME P450

Publications:
GuideToPharmacology: 1548
- Version: 29-September-2020
Alternate Names:

2610 HUGO Gene ID

2610 HUGO Gene Symbol

cytochrome P450 family 2 subfamily A member 6 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name CYP2 family

GuideToPharmacology Gene Category ID 262

Gene Categories:

ENZYME

Publications:

PharmGKB: CYP2A6

Version: 18-August-2020

Alternate Names:

PA121 PharmGKB ID

Gene Info:

Publications:

Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics

Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos

Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab

DrugBank: BE0003336
- Version: 5.1.7
Alternate Names:

CYP2A6 DrugBank Gene Name

P11509 UniProt Accession

1548 Entrez Gene Id

Gene Info:

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
DTC: CYP2A6
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:

Tani N et al., 2014, Rational design of novel CYP2A6 inhibitors., Bioorg Med Chem
HingoraniCasas: ENSG00000255974
- Version: 31-May-2017
Alternate Names:

ENSG00000255974 Gene Symbol

CYP2A6 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Pharos: CYP2A6
- Version: 03-September-2020
Alternate Names:

Cytochrome P450 2A6 Gene Name

P11509 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:
GO: CYP2A6
- Version: 05-September-2020
Alternate Names:

CYP2A3 GO Gene Synonym

Gene Info:

Gene Categories:

DRUG METABOLISM

Publications:
TTD: Cytochrome P450 2A6
- Version: 2020.06.01
Alternate Names:

CYP2A6 TTD Gene Abbreviation

T06455 TTD Target ID

Gene Info:

Publications:

ENSG00000198470	Ensembl Gene Id
CYTOCHROME P450 2A6 (EC 1.14.14.1) (CYPIIA6) (COUMARIN 7-HYDROXYLASE) (IIA3) (CYP2A3) (P450(I)). [SOURCE:UNIPROT/SWISSPROT;ACC:P11509]	Description
CYP2A6	Display Id

P11509	Uniprot Accession
CYP2A6	Uniprot Gene Name
ENSG00000255974	Ensembl Gene Id

2610	HUGO Gene ID
2610	HUGO Gene Symbol
cytochrome P450 family 2 subfamily A member 6	HUGO Gene Name

CYP2A6	DrugBank Gene Name
P11509	UniProt Accession
1548	Entrez Gene Id

CYP2A6 Gene Record

CYP2A6 1548 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12386121 19702528 19442086 11038165 14704462 8886611

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25458499

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25458499

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11394901 16679388 10544257 14583682 10923861 9827545 27339126 16041240 15900015 12325023 12844137 9409631 21521021 15993850 11779172 2322567 11278503 11038160

Sources: PharmGKB DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12386121 19702528 19442086 11038165 14704462 8886611

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25588294

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12386121 19702528 19442086 11038165 14704462 8886611

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12386121 19702528 19442086 11038165 14704462 8886611

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12386121 19702528 19442086 11038165 14704462 8886611

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Types & Directionality:

n/a

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10592235

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
10592235

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
10592235

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
25458499

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25458499

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11394901 16679388 10544257 14583682 10923861 9827545 27339126 16041240 15900015 12325023 12844137 9409631 21521021 15993850 11779172 2322567 11278503 11038160

Sources:
PharmGKB DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18064444 18979093 19926036 19851082 18350255 12920490 12844133

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10592235

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
25588294

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
26132489

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15940289 19238117 18698229 16378601 19921195 20155256 21494765 19604090 21521021 14981342

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26049587 11866476 9548799

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22960662

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19604090